Global Ophthalmology Market (By Segment – Surgical & Vision Care; By Disease - Retinal Disorder, Glaucoma & Dry Eye; By Drug Class – Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs; By Region – North America, Europe & Asia Pacific) Market Outlook 2025

May 2019 | 87 pages | ID: G41536315E2EN
Rockville Research

Abstracts

Ophthalmic drug delivery has been one of the most daunting task for clinicians. With the advent of novel drug delivery techniques, unique delivery systems of drug administration has been introduced into the market. Novel dosage form mainly comprises of microemulsions, nanosuspensions, dendrimers, niosomes, liposomes etc.

The report “Global Ophthalmology Market (By Segment – Surgical & Vision Care; By Disease - Retinal Disorder, Glaucoma & Dry Eye; By Drug Class – Anti Glaucoma Drugs, Dry Eye Drugs & Anti-infective Drugs; By Region – North America, Europe & Asia Pacific) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global ophthalmology market overall as well as across market segments such as by disease and by drug class for the period 2019-25. Regional analysis is done across major markets in North America, Europe and Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global ophthalmology market. The report has been segmented as following:-

Market Segmentation – Segments

• Surgical
• Vision Care

Market Segmentation – Disease

• Retinal Disorder
• Glaucoma
• Dry Eye

Market Segmentation – Drug Class

• Anti-Glaucoma Drugs
• Dry Eye Drugs
• Anti-Infective Drugs

Geographical Coverage

• North America – The US
• Europe – Germany & The UK
• Asia Pacific – China & India

Key Vendors

• Novartis AG
• Bausch & Lomb, Inc.
• F.Hoffman La-Roche
• Regeneron Pharmaceuticals, Inc.
• Allergan PLC

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. OPHTHALMOLOGY

3.1 Background
3.2 Eye Disorders

4. MARKET ANALYSIS

4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
  4.2.1 Market Share by Segment
  4.2.2 Market Share by Indication
  4.2.3 Market Share by Drug Class
  4.2.4 Market Share by Products
  4.2.5 Market Share by Product Type
  4.2.6 Market Share by Dosage Type
  4.2.7 Market Share by Region

5. MARKET SEGMENTATION

5.1 Segments
  5.1.1 Surgical
    5.1.1.1 Market Sizing (Actual & Forecasted)
    5.1.1.2 Implantable Market Sizing (Actual & Forecasted)
    5.1.1.3 Consumables Market Sizing (Actual & Forecasted)
    5.1.1.3 Equipment/Others Market Sizing (Actual & Forecasted)
  5.1.2 Vision Care
    5.1.2.1 Market Sizing (Actual & Forecasted)
    5.1.2.2 Contact Lenses Market Sizing (Actual & Forecasted)
    5.1.2.3 Contact Lenses Market Sizing (Actual & Forecasted)
5.2 Disease
  5.2.1 Retinal Disorder
    5.2.1.1 Market Sizing (Actual & Forecasted)
    5.2.1.2 Market Share by Disease Type
    5.2.1.3 nAMD Market Sizing (Actual & Forecasted)
    5.2.1.4 DME/DR Market Sizing (Actual & Forecasted)
    5.2.1.5 DME/DR Market Sizing (Actual & Forecasted)
  5.2.2 Glaucoma
    5.2.2.1 Market Sizing (Actual & Forecasted)
  5.2.3 Dry Eye
    5.2.3.1 Market Sizing (Actual & Forecasted)
5.3 Drug Class
  5.3.1 Anti-Glaucoma Drugs
  5.3.2 Dry Eye Drugs
  5.3.3 Anti-Infective Drugs

6. REGIONAL ANALYSIS

6.1 North America
  6.1.1 Market Sizing (Actual & Forecasted)
  6.1.2 The US
    6.1.2.1 Market Sizing (Actual & Forecasted)
    6.1.2.2 Market Share by Dosage Type
    6.1.2.3 Market Share by End-Users
6.2 Europe
  6.2.1 Market Sizing (Actual & Forecasted)
  6.2.2 Germany
    6.2.2.1 Market Sizing (Actual & Forecasted)
  6.2.3 The UK
    6.2.2.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
  6.3.1 Market Sizing (Actual & Forecasted)
  6.3.2 China
    6.3.2.1 Market Sizing (Actual & Forecasted)
  6.3.4 India
    6.3.4.1 Market Sizing (Actual & Forecasted)
    6.3.4.2 Market Share by Devices

7. MARKET DYNAMICS

7.1 Industry Trends & Development
  7.1.1 Mergers & Acquisitions
  7.1.2 Advent of Novel Drug Delivery Techniques
7.2 Growth Drivers
  7.2.1 Prevalence of Eye Disorder
  7.2.3 Rising R&D in the Industry
  7.2.4 Growing Geriatric Population
  7.2.5 Increasing Awareness
7.3 Challenges
  7.3.1 High Cost of Diagnosis & Treatment
  7.3.2 Patent Expiration of Blockbuster Ophthalmic Drugs
  7.3.3 Limited Insurance Coverage

8. COMPETITIVE LANDSCAPE

8.1 Market Share Analysis
8.2 Financial Analysis

9. COMPANY PROFILES

9.1 Novartis AG
9.2 Bausch & Lomb, Inc.
9.3 F.Hoffman La-Roche
9.4 Regeneron Pharmaceuticals, Inc.
9.5 Allergan PLC